KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 Injection for patients with diffuse large B-cell lymphoma.

Trial Details

NCT ID
NCT07260812
Phase
PHASE1
Sponsor
TCRx Therapeutics Co.Ltd
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • KSV01 Injection
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • Patients or their legal guardians voluntarily participate in the study and provide written informed consent.
  • Aged 18 to 80 years (inclusive), male or female.
  • ECOG performance status score of ≤ 1.
  • Life expectancy \> 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →